These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 20529284)

  • 1. The effect of pharmacological treatment on gait biomechanics in peripheral arterial disease patients.
    Huisinga JM; Pipinos II; Johanning JM; Stergiou N
    J Neuroeng Rehabil; 2010 Jun; 7():25. PubMed ID: 20529284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with pharmacological agents in peripheral arterial disease patients does not result in biomechanical gait changes.
    Huisinga JM; Pipinos II; Stergiou N; Johanning JM
    J Appl Biomech; 2010 Aug; 26(3):341-8. PubMed ID: 20841626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological treatment of intermittent claudication does not have a significant effect on gait impairments during claudication pain.
    Yentes JM; Huisinga JM; Myers SA; Pipinos II; Johanning JM; Stergiou N
    J Appl Biomech; 2012 May; 28(2):184-91. PubMed ID: 22723116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease.
    O'Donnell ME; Badger SA; Sharif MA; Young IS; Lee B; Soong CV
    J Vasc Surg; 2009 May; 49(5):1226-34. PubMed ID: 19217745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of cilostazol in the management of intermittent claudication.
    Chi YW; Lavie CJ; Milani RV; White CJ
    Vasc Health Risk Manag; 2008; 4(6):1197-203. PubMed ID: 19337533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between temporal-spatial gait parameters, gait kinematics, walking performance, exercise capacity, and physical activity level in peripheral arterial disease.
    Crowther RG; Spinks WL; Leicht AS; Quigley F; Golledge J
    J Vasc Surg; 2007 Jun; 45(6):1172-8. PubMed ID: 17543681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Joint torques and powers are reduced during ambulation for both limbs in patients with unilateral claudication.
    Koutakis P; Pipinos II; Myers SA; Stergiou N; Lynch TG; Johanning JM
    J Vasc Surg; 2010 Jan; 51(1):80-8. PubMed ID: 19837536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease.
    O'Donnell ME; Badger SA; Sharif MA; Makar RR; Young IS; Lee B; Soong CV
    Vasc Endovascular Surg; 2009; 43(2):132-43. PubMed ID: 19131370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Supervised walking exercise therapy improves gait biomechanics in patients with peripheral artery disease.
    Schieber MN; Pipinos II; Johanning JM; Casale GP; Williams MA; DeSpiegelaere HK; Senderling B; Myers SA
    J Vasc Surg; 2020 Feb; 71(2):575-583. PubMed ID: 31443974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication.
    Stevens JW; Simpson E; Harnan S; Squires H; Meng Y; Thomas S; Michaels J; Stansby G
    Br J Surg; 2012 Dec; 99(12):1630-8. PubMed ID: 23034699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a long-term exercise program on lower limb mobility, physiological responses, walking performance, and physical activity levels in patients with peripheral arterial disease.
    Crowther RG; Spinks WL; Leicht AS; Sangla K; Quigley F; Golledge J
    J Vasc Surg; 2008 Feb; 47(2):303-9. PubMed ID: 18241753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gait variability is altered in patients with peripheral arterial disease.
    Myers SA; Johanning JM; Stergiou N; Celis RI; Robinson L; Pipinos II
    J Vasc Surg; 2009 Apr; 49(4):924-931.e1. PubMed ID: 19217749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral artery disease causes consistent gait irregularities regardless of the location of leg claudication pain.
    Rahman H; Leutzinger T; Hassan M; Schieber M; Koutakis P; Fuglestad MA; DeSpiegelaere H; Longo GM; Malcolm P; Johanning JM; Casale GP; Pipinos II; Myers SA
    Ann Phys Rehabil Med; 2024 Apr; 67(3):101793. PubMed ID: 38118246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral arterial disease affects kinematics during walking.
    Celis R; Pipinos II; Scott-Pandorf MM; Myers SA; Stergiou N; Johanning JM
    J Vasc Surg; 2009 Jan; 49(1):127-32. PubMed ID: 19028062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials.
    Regensteiner JG; Ware JE; McCarthy WJ; Zhang P; Forbes WP; Heckman J; Hiatt WR
    J Am Geriatr Soc; 2002 Dec; 50(12):1939-46. PubMed ID: 12473004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gait alterations associated with walking impairment in people with peripheral arterial disease with and without intermittent claudication.
    McDermott MM; Ohlmiller SM; Liu K; Guralnik JM; Martin GJ; Pearce WH; Greenland P
    J Am Geriatr Soc; 2001 Jun; 49(6):747-54. PubMed ID: 11454113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coactivation pattern in leg muscles during treadmill walking in patients suffering from intermittent claudication.
    Guilleron C; Maktouf W; Beaune B; Henni S; Abraham P; Durand S
    Gait Posture; 2021 Feb; 84():245-253. PubMed ID: 33383535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cilostazol for peripheral arterial disease.
    Robless P; Mikhailidis DP; Stansby GP
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003748. PubMed ID: 18254032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cilostazol for peripheral arterial disease.
    Robless P; Mikhailidis DP; Stansby GP
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003748. PubMed ID: 17253494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease.
    Money SR; Herd JA; Isaacsohn JL; Davidson M; Cutler B; Heckman J; Forbes WP
    J Vasc Surg; 1998 Feb; 27(2):267-74; discussion 274-5. PubMed ID: 9510281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.